← Back to patent-cliff list
CAS 5173-46-6
(8S,13S,14S)-13-methyl-1,6,7,8,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dioneEstra-4,9-diene-3,17-dione
Codes: MIFE-010, (I)90248-3-a, (VI)125457-3-a
Application context (from source-drug indications)
Termination of pregnancyMifepristone/MisoprostolContraceptionDienogest/Estradiol ValerateMenorrhagiaDienogest/Estradiol ValerateContraceptive useDienogest/Estradiol ValeratePelvic painDienogest/Estradiol ValerateHeadacheDienogest/Estradiol ValerateDysmenorrhoeaDienogest/Estradiol ValerateCushing's syndromeMifepristoneTermination of pregnancyMifepristoneContraceptionMifepristonePost-traumatic stress disorderMifepristoneMajor depressive disorderMifepristonePsychological traumaMifepristoneContraceptionDienogestEndocrine system disorderDienogestEndometriosisDienogestAdenomyosisDienogestPainDienogest
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Mifepristone/Misoprostol | Tier C — Watch / trade | - |
| Dienogest/Estradiol Valerate | Tier C — Watch / trade | - |
| Mifepristone | Tier C — Watch / trade | - |
| Dienogest | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(8R,13S,14S)-10-(hydroxymethyl)-13-methyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8S,13S,14S)-13-methyl-3,17-dioxo-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl acetate→(8S,13S,14S)-13-methyl-1,6,7,8,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
Estra-4,9-diene-3,17-dione→1,3-Dihydroxy-2,2-dimethylpropane→3,3-(2,2-Dimethyl-1,3-propylenedioxy)estra-5(10),9(11)-dien-17-one→3,3-(2,2-Dimethyl-1,3-propylenedioxy)-17beta,17beta-(methyleneoxy)estra-5(10),9(11)-diene→2-[3,3-(2,2-Dimethyl-1,3-propylenedioxy)-17beta-hydroxyestra-5(10),9(11)-dien-17-yl]acetonitrile
2-(3-Chloropropyl)-2,5,5-trimethyl-1,3-dioxane→2-(3-Bromopropyl)-2,5,5-trimethyl-1,3-dioxane→(6aS,9aS,9bS)-6a-Methyldecahydrocyclopenta[f]chromene-3,7-dione→(3aS,4S,7aS)-5-Hydroxy-7a-methyl-4-[3-oxo-6-(2,5,5-trimethyl-1,3-dioxan-2-yl)hexyl]octahydro-1H-inden-1-one→(3aS,4S,7aS)-7a-Methyl-4-[3-oxo-6-(2,5,5-trimethyl-1,3-dioxan-2-yl)hexyl]hexahydro-1H-indene-1,5(4H)-dione→(3aS,9aS,9bS)-3a-Methyl-6-[2-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]-4,5,8,9,9a,9b-hexahydro-1H-cyclopenta[a]naphthalene-3,7(2H,3aH)-dione→Estra-4,9-diene-3,17-dione
(8R,13S,14S)-10-(hydroxymethyl)-13-methyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8S,13S,14S)-13-methyl-3,17-dioxo-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl acetate→(8S,13S,14S)-13-methyl-1,6,7,8,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
Estra-4,9-diene-3,17-dione→1,3-Dihydroxy-2,2-dimethylpropane→3,3-(2,2-Dimethyl-1,3-propylenedioxy)estra-5(10),9(11)-dien-17-one→3,3-(2,2-Dimethyl-1,3-propylenedioxy)-17beta,17beta-(methyleneoxy)estra-5(10),9(11)-diene→2-[3,3-(2,2-Dimethyl-1,3-propylenedioxy)-17beta-hydroxyestra-5(10),9(11)-dien-17-yl]acetonitrile
2-(3-Chloropropyl)-2,5,5-trimethyl-1,3-dioxane→2-(3-Bromopropyl)-2,5,5-trimethyl-1,3-dioxane→(6aS,9aS,9bS)-6a-Methyldecahydrocyclopenta[f]chromene-3,7-dione→(3aS,4S,7aS)-5-Hydroxy-7a-methyl-4-[3-oxo-6-(2,5,5-trimethyl-1,3-dioxan-2-yl)hexyl]octahydro-1H-inden-1-one→(3aS,4S,7aS)-7a-Methyl-4-[3-oxo-6-(2,5,5-trimethyl-1,3-dioxan-2-yl)hexyl]hexahydro-1H-indene-1,5(4H)-dione→(3aS,9aS,9bS)-3a-Methyl-6-[2-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]-4,5,8,9,9a,9b-hexahydro-1H-cyclopenta[a]naphthalene-3,7(2H,3aH)-dione→Estra-4,9-diene-3,17-dione
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.